[Triple-therapy treatment during 1 month versus 2 weeks in gastroduodenal disease due to Helicobacter pylori in children]

An Esp Pediatr. 1996 May;44(5):456-60.
[Article in Spanish]

Abstract

The aim of this study was to assess the clinical outcome of two different durations of triple therapy in children with Helicobacter pylori infection. We established two treatment groups: 1) Short treatment, including 2 week of bismuth subcitrate, amoxycillin and metronidazole treatment (n = 21) and 2) Long treatment, which included the same therapy for two weeks plus bismuth subcitrate alone for two weeks more (n = 26). We found no difference between the short and long treatments. The infection remained in 14% and 19%, respectively. In both groups, we observed children (19%) with persistent abdominal pain in spite of Helicobacter pylori eradication and gastritis healing. We conclude that it is not necessary to prolong triple therapy more than 2 weeks in order to have therapeutic success.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Amoxicillin / administration & dosage
  • Anti-Bacterial Agents / administration & dosage
  • Bismuth / administration & dosage
  • Child
  • Child, Preschool
  • Drug Evaluation
  • Drug Therapy, Combination
  • Duodenitis / drug therapy*
  • Female
  • Gastritis / drug therapy*
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori*
  • Humans
  • Male
  • Metronidazole / administration & dosage
  • Organometallic Compounds / administration & dosage
  • Penicillins / administration & dosage
  • Time Factors

Substances

  • Anti-Bacterial Agents
  • Organometallic Compounds
  • Penicillins
  • Metronidazole
  • Amoxicillin
  • bismuth tripotassium dicitrate
  • Bismuth